North Dakota Bipartisan $25 Insulin Cap Enacted; Self-Funded Plans Excluded

North Dakota enacted a bipartisan law capping insulin costs at $25 for a 30-day supply on state-regulated plans.

“Typically, Republicans are more on the free-market side of things, Democrats are more supportive of intervening,” North Dakota state Sen. Sean Cleary said.

“But in this case, I think there was broad-enough agreement that this market just wasn’t functioning for folks.”

That consensus produced House Bill 1114, enacted in March 2025, which caps out-of-pocket insulin costs at $25 for a 30-day supply for patients on state-regulated health plans and adds a separate $25 reimbursement for syringes and pen needles.

The stakes are concrete. The Kritzberger family, farming in the Red River Valley near Hillsboro, spends $8,000 or more each year on medication, supplies and appointments for their 17-year-old daughter Nina, who has Type 1 diabetes, despite carrying insurance. “I slept by her bedside for the first 60 days,” Ang Kritzberger told NPR.

“And I had to stick her finger every two hours, 24 hours a day, to make sure that she was OK.” Nina, now 17, manages a daily arsenal: “I have to make sure I have insulin, a spare pump, a spare Dexcom… Oh, what if my pump doesn’t work, or my Dexcom? Then I have to bring a testing kit. What if I go low? I need Gatorade, glucose.”

North Dakota’s Bipartisan Push To Cap Insulin Costs — KFF Health News and NPR

For patients whose plans fall under the new law, the savings are immediate. Someone previously paying $100 a month saves $75 per refill; someone paying $300 saves $275. The $25 cap applies even before a high deductible is met — a lifeline for families on high-deductible plans who previously faced thousands in upfront costs.

Nationally, average annual out-of-pocket insulin spending for people with private insurance fell from $470 in 2018 to $220 in 2025, according to KFF Health News, but averages mask the burden on families managing complex care.

The law’s reach, however, has sharp edges. It covers individual marketplace plans and fully insured employer plans — those bought from a commercial carrier. It does not cover self-funded employer plans, where the employer pays claims directly. Under the federal Employee Retirement Income Security Act, those plans are exempt from state insurance mandates.

That means two neighbors in North Dakota can face vastly different prices at the pharmacy counter depending on how their employer structures benefits. Medicare beneficiaries, meanwhile, fall under a separate federal cap of $35 a month set by the Inflation Reduction Act.

Insurers and business groups fought the mandate. Blue Cross Blue Shield of North Dakota lobbyist Megan Hruby warned lawmakers that coverage mandates do not automatically make health insurance more affordable overall, arguing the cost would shift to premiums for other policyholders. Supporters countered with data from the state employee program, which lowered patient costs without significant premium spikes.

Rep. Carrie McLeod, a Republican and diabetes educator, told legislators the system had drifted too far toward financial returns: “The insurance companies started out to really help people with catastrophic needs, but things have gotten out of control.” The bill passed both chambers by wide bipartisan margins.

North Dakota is the 29th state, plus the District of Columbia, to enact an insulin copay cap, according to the American Diabetes Association. Colorado passed the first in 2019 at $100 per 30-day supply; later states adopted stricter limits ranging from $25 to $35.

The details vary: some cap per prescription, others cap a patient’s total 30-day supply, and only a handful extend protections to diabetes supplies or devices like continuous glucose monitors and insulin pumps — costs the North Dakota law does not cover.

North Dakota Bipartisan $25 Insulin Cap Enacted; Self-Funded Plans Excluded
Photo: npr.org

Federal momentum is building. The INSULIN Act (S. 4189), which would cap insulin costs for privately insured and employer-sponsored patients at $35 a month, cleared the Senate Health, Education, Labor, and Pensions Committee with bipartisan support in July 2026.

Companion legislation (H.R. 10227) was introduced in the House in September. “Federal lawmakers are also considering broader protections,” healthcare policy analyst Anne Kamwila told Blavity Health. “If enacted, it would provide coverage to some individuals who are not currently covered by Medicare’s cap.”

Cleary, a third-generation Bismarck resident born in 1991, earned a master’s in applied economics from the University of North Dakota after a bachelor’s from the University of Mary. He worked on the staff of U.S. Senator John Hoeven and later Governor Doug Burgum, and served as campaign manager for Julie Fedorchak’s successful 2024 U.S. House race.

Before winning his Senate seat, he was a project manager for a technology cooperative serving rural electric utilities and a grant writer for the Theodore Roosevelt Medora Foundation.

Until a nationwide standard becomes law — and until policymakers address the high price of continuous glucose monitors, insulin pumps, and routine care — a patient’s zip code and insurance type will continue to dictate how affordable diabetes management truly is.